L1 Endonuclease Inhibitor Compositions for Age-Associated Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for better treatment and prevention of age-related inflammation and associated disorders, as current understanding of the mechanisms controlling age-related inflammation is limited, and existing treatments are inadequate.
Innovation Solution
Administering a long interspersed nuclear element 1 (LINE-1) endonuclease inhibitor to patients in need, which targets the L1 EN domain to reduce age-associated inflammation and its underlying mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If L1 retrotransposition is inhibited to reduce age-associated inflammation, then inflammatory markers are reduced, but DNA damage may increase due to endonuclease activity
Solution Approach 1:
The invention divides the L1 retrotransposition process into two separable targets: the endonuclease (EN) domain and the reverse transcriptase (RT) domain. By developing inhibitors that selectively target the EN domain (such as compounds AD1-AD55), the patent achieves suppression of L1-induced inflammation without completely blocking retrotransposition, thereby reducing inflammatory markers while minimizing DNA damage from endonuclease activity.
2Stability of the object's composition
If L1 endonuclease activity is suppressed to reduce DNA damage, then genomic stability is improved, but retrotransposition and associated inflammation may increase
Solution Approach 1:
The invention uses small molecule inhibitors (AD1-AD55) as intermediaries that specifically bind to the L1 endonuclease domain. These compounds act as mediators that block the endonuclease's DNA cleavage activity, preventing DNA damage and maintaining genomic stability, while allowing the reverse transcriptase domain to continue its function, thereby balancing genomic protection with controlled retrotransposition to minimize inflammatory responses.
3Object-generated harmful factors
If broad L1 retrotransposition inhibition is used to treat age-related diseases, then inflammation is reduced, but off-target effects on mitochondrial polymerase may occur
Solution Approach 1:
The invention applies local quality by designing inhibitors (AD1-AD55) with specific structural features that confer selectivity for the L1 endonuclease domain over other polymerases. The compounds exhibit differential binding affinity, showing IC50 values in the nanomolar range for L1 EN while having minimal effect on mitochondrial polymerase gamma and other cellular polymerases, thereby achieving localized inhibition of the target enzyme without broad off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The L1 EN inhibitors effectively reduce age-associated inflammation and its associated pathologies, such as Alzheimer's disease and Parkinson's disease, by inhibiting the L1 EN domain, thereby mitigating DNA damage and pro-inflammatory states.
Implementation Method 1
Administering a long interspersed nuclear element 1 (LINE-1) endonuclease inhibitor to patients in need, which targets the L1 EN domain to reduce age-associated inflammation and its underlying mechanisms
Implementation Method 2
The one or more L1 EN inhibitors inhibit L1 reverse transcriptase activity in a cell
Data Source
AI summary
Disclosed are methods for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one long interspersed nuclear element 1 (LINE-1, L1) endonuclease inhibitor (L1 EN inhibitor), either alone or in combination with at least one additional therapeutic agent. Effectiveness of the methods can be measured via biomarkers and/or by a decrease in symptoms compared to those symptoms before administration of the L1 EN inhibitor. Specific chemical structures of the L1 EN inhibitors are identified and shown herein.